Glycopeptide antibiotics are derived from actinomycete with exclusive trycyclic or tetracyclic heptapeptide cores that are generally glycosylated and at times have added lipophilic fatty acid side chains.
Globally, the market of glycopeptide antibiotics is projected to be priced at US$ 2,860.5 Mn in the year 2022 and is anticipated to show a CAGR of 4.2% in the predicted period from 2022 to 2030.
Request Sample of this Strategic Report (Use Corporate Mail ID for Top Priority) –https://www.coherentmarketinsights.com/insight/request-sample/5455
The rise in number of cancer cases and communicable diseases like Hepatitis, enterococcal infections and others is anticipated to push the growth of the market in the predicted period. For example, as per the data issued by the Centers for Disease Control and Prevention (CDC) in September 2022, tuberculosis cases in 2019 in the U.S were 8,916.
Rising product consents for treating communicable diseases are anticipated to push the growth of the market in the predicted period. For example, in July 2021, Abbvie Inc. which is a biopharmaceutical company in U.S. declared that United States Food and Drug Administration (US FDA) had consented DALVANCE for treating skin structure infections (ABSSSI) and acute bacterial skin.
The pandemic of COVID-19 substantially affected the market of glycopeptide antibiotics. Interruptions and disruption of appointments at the clinical trials, obstacles in recruiting patients for clinical trials and studies were either cancelled or delayed. Though, the adverse effect was slowly abridged by many strategic procedures undertaken by the government, stakeholders at the market to safeguard the steadiness of R&D (research and development) activities and the regulatory bodies. Owing to the vaccines, therapies and diagnostics urgent demand, the medical trials were initiated by adherence of social distancing methods. Furthermore, to care for the medical trials of the COVID-19 vaccines as well as treatments, public establishments worldwide financed in the R&D activities. For example, as per an article issued in BMJ Publishing Group Ltd. which is a U.K. based publisher of medical journals, subsequently in January 2020, the U.K. Government was the main funder of Oxford-AstraZeneca vaccine research and development , adding £33,354,469 (US$ 36,762,962) (95.5%). The portion for charitable funders reported for £1,217,835 (US$ 1,342,286) (3.5%), the bulk portion was from Welcome Trust. Across the globe, the sites which conducted clinical trials, excluding COVID-19, witnessed timeline delays. At times, many clinical trials reached shut down of many operations therefore affecting outcomes of the clinical research. The U.S. Food and Drug Administration in March 2020 issued a document for guidance on the Conduct of Clinical Trials of Medical Products at the time of the pandemic. The same set of guideline sustained the clinical trial operations recovery and the figure is anticipated to rise with time.
The main causes that hamper the growth of the glycopeptide antibiotics market worldwide comprise rise in glycopeptide antibiotic cases of resistances. For example, as per Antibiotic Resistance Threat Report in the U.S. in 2019, Enterococcus which is Vancomycin, glycopeptide antibiotic, resistant bacteria caused deaths of about 5,400 in the year 2019 in the United States.
The main companies functioning in the market of glycopeptide antibiotic are ANI Pharmaceuticals, Inc., Fresenius SE & Co. KGaA, Pfizer Inc., Mylan N.V., Novartis AG, Hikma Pharmaceuticals plc, Aurobindo Pharma, AbbVie Inc., Melinta Therapeutics, Inc, Cumberland Pharmaceuticals Inc., Theravance Biopharma, Janssen Global Services, LLC, Bristol-Myers Squibb Company, and GlaxoSmithKline plc.
Request-Customization @ https://www.coherentmarketinsights.com/insight/request-customization/5455
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug
- Market Snippet, By Disease Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Drivers
- Restraints
- Opportunities
- Impact Analysis
- Key Development Strategies
- Mergers And Acquisition Scenario
- Market Trends
- Brand Analysis
- Regulatory Scenario
- PEST Analysis
- Pricing Analysis
- Global Glycopeptide Antibiotics Market – Impact of Coronavirus (Covid-19) Pandemic
- COVID-19 Epidemiology
- Impact on Manufacturing
- Impact on Manufacturing
- Global Glycopeptide Antibiotics Market, By Drug, 2017 – 2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017–2030
- Segment Trends
- Vancocin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
- Orbactiv
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
- Dalvance
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
- Kimyrsa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
- Introduction
- Global Glycopeptide Antibiotics Market, By Disease Indication, 2017 – 2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017–2030
- Segment Trends
- Clostridium difficile-associated Diarrhea
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
- Endocarditis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
- Skin Structure Infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
- Introduction
- Global Glycopeptide Antibiotics Market, By Distribution Channel, 2017 – 2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017–2030
- Segment Trends
- Hospital Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
- Retail Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
- Online Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
- Introduction
- Global Glycopeptide Antibiotics Market, By Region, 2017 – 2030, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017–2030
- North America
- Market Size and Forecast, By Drug, 2017 – 2030, (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2017 – 2030, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2030, (US$ Mn)
- Market Size and Forecast, By Country, 2017 – 2030, (US$ Mn)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Drug, 2017 – 2030, (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2017 – 2030, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2030, (US$ Mn)
- Market Size and Forecast, By Country, 2017 – 2030, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Size and Forecast, By Drug, 2017 – 2030, (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2017 – 2030, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2030, (US$ Mn)
- Market Size and Forecast, By Country, 2017 – 2030, (US$ Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Drug, 2017 – 2030, (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2017 – 2030, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2030, (US$ Mn)
- Market Size and Forecast, By Country, 2017 – 2030, (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Market Size and Forecast, By Drug, 2017 – 2030, (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2017 – 2030, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2030, (US$ Mn)
- Market Size and Forecast, By Country, 2017 – 2030, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Drug, 2017 – 2030, (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2017 – 2030, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2030, (US$ Mn)
- Market Size and Forecast, By Region/Country, 2017 – 2030, (US$ Mn)
- South Africa
- Central Africa
- North Africa
- Introduction
- Competitive Landscape
- Competitive Snapshot
- ANI Pharmaceuticals, Inc.*
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Fresenius SE & Co. KGaA
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Pfizer Inc
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Mylan N.V.
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Novartis AG
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Hikma Pharmaceuticals plc
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Aurobindo Pharma
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- AbbVie Inc.
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Melinta Therapeutics, Inc
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Cumberland Pharmaceuticals Inc
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Theravance Biopharma
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Janssen Global Services, LLC
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Bristol-Myers Squibb Company
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- GlaxoSmithKline plc.
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Competitive Snapshot
- Section
- References
- Research Methodology
- About us and Sales Contact
About Coherent Market Insights
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact us:
Mr. Shah
Coherent Market Insights
533 Airport Boulevard, Suite 400,
Burlingame, CA 94010, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com